Industry & Policy News

[Kyverna Therapeutics] Kyverna Therapeutics announced the signing of a multi-year research funding agreement with Charité – Universitätsmedizin Berlin to investigate the impact of B- and plasma cell-targeting therapies on the immunologic profile and clinical outcomes of patients with systemic autoimmune diseases.

[L2P Researcher] This grant will explore a cell therapy approach for the treatment of osteoarthritis via delivery of human MSC and adipose-derived stem cells in the form of three-dimensional hydrogels.

[NexImmune, Inc.] NexImmune, Inc. announces the extension of the research partnership between NexImmune, Yale, and JDRF to explore the use of NexImmune’s AIM nanoparticles in combination with an anti-CD3 mAb to tolerize, deplete, or modulate diabetes antigen-specific T cells.

[Kyverna Therapeutics] Kyverna Therapeutics announced the signing of a multi-year research funding agreement with Charité – Universitätsmedizin Berlin to investigate the impact of B- and plasma cell-targeting therapies – including CAR T cells – on the immunologic profile and clinical outcomes of patients with systemic autoimmune diseases.

[ResoTher Pharma (PR Newswire)] ResoTher Pharma announced that the company has received a €2.5 million grant from the EIC to support the development of the company's Lead Compound, RTP-026, in a Phase IIa clinical study in myocardial infarction.

[Novartis] Cosentyx is the only FDA-approved fully human biologic that directly inhibits interleukin-17A, a cytokine believed to be involved in the inflammation of hidradenitis suppurativa.